The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Blood Based Biomarkers Market Change Between 2026 And 2030?

The blood based biomarkers market has witnessed swift expansion in recent years. It is forecast to grow from $25.83 billion in 2025 to $28.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. This historical development can be ascribed to advancements in molecular diagnostics, the proliferation of cancer screening programs, rigorous biomarker validation studies, improvements in hospital diagnostic infrastructure, and an increase in research funding.

The market for blood based biomarkers is projected to experience substantial expansion in the coming years. Its valuation is set to reach $45.5 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.0%. Factors contributing to this growth over the forecast period include the expanding application of liquid biopsy, advancements in AI-powered biomarker analytics, the increasing need for chronic disease monitoring, the wider acceptance of personalized medicine, and the rise of point-of-care testing. Key trends anticipated during this period encompass the increasing integration of non-invasive diagnostics, the broadening scope of precision oncology applications, greater utilization in the early detection of diseases, a surge in demand for personalized treatment monitoring, and the incorporation with clinical decision support systems.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp

What Important Drivers Are Powering The Blood Based Biomarkers Market Growth?

The increasing incidence of cardiovascular diseases is projected to drive the expansion of the blood-based biomarkers market in the foreseeable future. These diseases encompass a range of ailments impacting the heart and its vessels, such as coronary artery disease, heart failure, and stroke. This surge in cardiovascular conditions is primarily attributable to escalating risk factors, including inadequate dietary habits and an upward trend in obesity levels. Blood-based biomarkers assist in the diagnosis and monitoring of cardiovascular illnesses by offering clarity on disease advancement, evaluating risks, and assessing treatment efficacy through quantifiable elements present in the bloodstream. As an illustration, the National Center for Biotechnology Information, a US-based government agency, issued a global health research report in September 2024. This report forecast a 90% increase in cardiovascular disease prevalence from 2025 to 2050, predicting cardiovascular fatalities to reach 35.6 million by 2050. Consequently, the escalating number of cardiovascular disease occurrences is fueling the expansion of blood-based biomarkers.

What Are The Core Segment Classifications In The Blood Based Biomarkers Market?

The blood based biomarkers market covered in this report is segmented –

1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers

2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies

3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications

4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users

Subsegments:

1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions

2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins

3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels

4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells

5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity

Which Trends Are Supporting The Evolution Of The Blood Based Biomarkers Market?

Companies operating in the blood-based biomarkers market are focusing on technological advancements such as high-accuracy blood biomarker tests to aid physician diagnosis of Alzheimer’s disease. A high-accuracy blood biomarker test is a diagnostic tool that utilizes specific biomarkers in the blood to detect diseases or monitor health conditions with a high level of precision and reliability. For instance, in October 2023, Quanterix, a US-based life sciences company, launched a high-accuracy blood biomarker test named LucentAD p-Tau 217 to assist physicians in diagnosing Alzheimer’s disease (AD) in adults with cognitive impairment. This test measures phosphorylated tau protein at threonine 217 (p-Tau 217), a biomarker strongly associated with AD pathology, particularly amyloid buildup in the brain. The LucentAD p-Tau 217 test achieves over 90% accuracy, meeting stringent diagnostic criteria, and is intended to be used alongside other diagnostic tools rather than as a standalone test.

Which Firms Are Competing In The Blood Based Biomarkers Market?

Major companies operating in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG

Access The Complete Blood Based Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/blood-based-biomarkers-global-market-report

Which Region Is The Dominant Market In The Blood Based Biomarkers Market?

North America was the largest region in the blood-based biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Blood Based Biomarkers Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp

Browse Through More Reports Similar to the Global Blood Based Biomarkers Market 2026, By The Business Research Company

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model